Global Endometrial Cancer Market 2018-2023: Segmented by Type of Cancer, Therapy, and Diagnosis Method - Growth, Trends, and Forecasts

  • ID: 4388561
  • Report
  • Region: Global
  • 111 Pages
  • Mordor Intelligence
UP TO OFF
until Dec 31st 2018
1 of 5
The Global Endometrial Cancer Market is Expected to Reach USD 26.09 Billion in 2023, at an Estimated CAGR of 3.9% During 2018-2023

FEATURED COMPANIES

  • Abbott Laboratories
  • Ariad Pharmaceuticals
  • Becton, Dickinson & Co.
  • Glaxosmithkline
  • Merck
  • Novartis Ag
  • MORE

The global endometrial cancer market is expected to reach USD 26.09 billion in 2023, with an estimated CAGR of 3.9% during 2018-2023 (the forecast period).

North America dominates the market, due to high incidence of uterine serious carcinoma. Endometrial cancer is a common form of cancer of the female reproductive system, which initiates in the lining of the uterus. The National Cancer Institute recorded that the number of new cases of endometrial cancer was 25.4 per 100,000 women per year, based on the 2009-2013 cases studied. Endometrial cancer is most frequently diagnosed among women aged 55-64 years.

Rise in Awareness about Uterine Diseases and their Available Therapies

Endometrial cancer is the fifth most common cause of cancer among women in the world. Thus, improving awareness of risk factors for endometrial cancer is very important. WHO, other government and non-government health organizations are strategizing for the fight against endometrial cancer. The US Department of Health and Human Service collaborated with Centers for Disease Control and Prevention (CDC) to develop a campaign to raise awareness among women and healthcare providers about the signs, symptoms, and risk factors of endometrial cancer. Endometrial cancer, if detected at an early stage, can be cured, and moreover, the treatment choices depend on where the cancer is and how much it is grown.

Additionally, high prevalence of endometrial cancer, growing prevalence of obesity in women, and recurrence of endometrial cancer after treatment with chemotherapy fuel the growth of the global endometrial cancer market.

High Cost Associated with Treatment

Treatment cost is one of the biggest concerns for cancer patients. In Japan, the total medical cost for each course, including supportive care and treatment for chemotoxic symptoms, ranged between JPY 22,230-590,140 (USD?278-7377). In endometrial cancer, cost of chemotherapeutic agents, laboratory tests, and oral medications were factors related to the total medical care costs. Hence, high costs hinder the growth of the global endometrial cancer market.
Additionally, low success rates in clinical trials for cancer drugs and adverse side-effects of treatment and high toxicity of endometrial cancer drugs also restrain the growth of the global endometrial cancer market.

North America to dominate the market

The global endometrial cancer market can be classified by type of therapy into surgery, immunotherapy, radiation therapy, chemotherapy, and follow-up treatment. The global endometrial cancer market, by diagnosis type, can be divided into biopsy, pelvic ultrasound, hysteroscopy, dilation and curettage, and CT scan. By geography it is segmented into - North America, Europe, Asia-Pacific, Middle East & Africa, and South America.
North America dominates the market, due to high incidence of uterine carcinoma, according to the National Cancer Institute, endometrial cancer is the fourth most common cause of cancer among women in the United States (US) and these numbers are expected to increase in the forecast period.

Key Developments in the Market

May 2017: Merck & Co.’s immunotherapy Keytruda is the first cancer drug approved by the US Food and Drug Administration (FDA), based on a patients’ specific genetic traits, regardless of where in the body the disease originated. Tumors with those traits are most common in colorectal, endometrial, and gastrointestinal cancers.

Major Players: Ariad Pharmaceuticals, Abbott Laboratories, Becton, Dickinson & Co., Glaxosmithkline, Merck, Novartis AG, Sanofi, Siemens Healthcare, Roche, amongst others.

Reasons to Purchase this Report

  • Current and future Global Endometrial Cancer market outlook in the developed and emerging markets
  • Analyzing various perspectives of the market with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3 months analyst support along with the Market Estimate sheet (in excel)

Market Dynamics

Market Drivers

  • Rise in Awareness About Uterine Disease and Their Available Therapies
  • High Prevalance of Endometrial Cancer
  • Growing Obesity in Women
  • Recurrenece of Endometrial Cancer After Treatment

Market Restraints

  • High Cost Associated With Treatments
  • Low Success Rates in Clinical Trials for Cancer Drugs
  • Adverse Side Effects of Treatement and High Toxicity of Drugs

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Ariad Pharmaceuticals
  • Becton, Dickinson & Co.
  • Glaxosmithkline
  • Merck
  • Novartis Ag
  • MORE

1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rise in Awareness About Uterine Disease and Their Available Therapies
6.1.2 High Prevalance of Endometrial Cancer
6.1.3 Growing Obesity in Women
6.1.4 Recurrenece of Endometrial Cancer After Treatment
6.2 Market Restraints
6.2.1 High Cost Associated With Treatments
6.2.2 Low Success Rates in Clinical Trials for Cancer Drugs
6.2.3 Adverse Side Effects of Treatement and High Toxicity of Drugs
6.3 Market Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 Segementation by Type of Therapy
7.1.1 Surgery
7.1.2 Immunotherapy
7.1.3 Radiation Therapy
7.1.4 Chemotherapy
7.1.4.1 Paclitaxel
7.1.4.2 Carboplatin
7.1.4.3 Doxorubicin or Liposomal Doxorubicin
7.1.4.4 Cisplatin
7.1.4.5 Others
7.1.5 Follow-Up Treatment
7.1.6 Others
7.2 Segementation by Diagnosis Method
7.2.1 Biopsy
7.2.2 Pelvic Ultrasound
7.2.3 Hysteroscopy
7.2.4 Dilation and Curettage
7.2.5 CT Scan
7.2.6 Others
7.3 Segementation by Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East and Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East and Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America

8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches

9. Company Profiles
9.1 Ariad Pharmaceuticals
9.2 Abbott Laboratories
9.3 Becton, Dickinson & Co.
9.4 Glaxosmithkline
9.5 Merck
9.6 Novartis Ag
9.7 Sanofi
9.8 Siemens Healthcare
9.9 Roche
9.10 Others

10. Future Outlook of the Market

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Laboratories
  • Ariad Pharmaceuticals
  • Becton, Dickinson & Co.
  • Glaxosmithkline
  • Merck
  • Novartis Ag
  • Roche
  • Sanofi
  • Siemens Healthcare
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll